|
Public |
|
| Healthcare & Pharmaceuticals - Diagnostic Laboratories | |
| around $2.5 - 5M | |
| around 20 - 50 | |
| www.biocept.com | |
| (858) 320-8200 | |
| (858) 320-8225 | |
Biocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company's Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. The Company commercializes its Target-Selector assays for a range of solid tumor indications, such as ... (Source: SEC reports)
Competitor - 1/9
Which company is more competitive with Biocept Inc?
Nov 5, 2018 17:23:03
SAN DIEGO, Nov. 5, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the [...]
Sep 13, 2018 05:22:23
SAN DIEGO, Sept. 10, 2018 /PRNewswire/ --Â Biocept, Inc. (NASDAQ : BIOC ), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to [...]
Sep 10, 2018 16:57:32
SAN DIEGO, Sept. 10, 2018 /PRNewswire/ --Â Biocept, Inc. (NASDAQ : BIOC ), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to [...]
Sep 5, 2017 21:36:46
SAN DIEGO, Sept. 5, 2017 /PRNewswire/ --Â Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve [...]
Aug 17, 2017 21:37:00
SAN DIEGO, Aug. 17, 2017 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to [...]